Prostacyclin Pathway Agent
Phase 3
Prostacyclin Pathway Agent is one of 4 therapeutic programs targeting Pulmonary Arterial Hypertension (PAH). It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
4 competitors in Pulmonary Arterial Hypertension (PAH)
#DrugCompanyPhaseTrials
1Prostacyclin Pathway Agent
UUniversity of Sao Paulo General Hospital
Phase 3
Intropin
PfizerPreclinical
Levophed
GGeneral Hospital of Ningxia Medical University
Preclinical
Adrenaline
SSamson Clinical Operations Pty Ltd
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Prostacyclin Pathway Agent. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]